Assessment of quality of life (QOL) improvement by moisturizer to radiation dermatitis accompanying radiation therapy after breast conserving surgerysurgery

Assessment of quality of life (QOL) improvement by moisturizer to radiation dermatitis accompanying radiation therapy after breast conserving surgerysurgery - QOL improvement by moisturizer to radiation dermatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026987

Enrollment

300

Registered

2017-10-11

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Radiation dermatitis

Interventions

Moisturizing agent application group Heparinoid cream From start of radiation therapy Twice daily Using 1FTU on irradiated skin Non moisturizing agent application group No use of any moisturi

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Patients planning to conduct radiation therapy after breast-conserving surgery at our hospital radiotherapy department at a dose of less than a divided dose (dose: 2.66 Gy / day total dose 42.56 Gy irradiation energy: 4 MV or 6 MV) (whether or not boost irradiation is asked Absent) 2)Patients who can understand the Japanese DLQI question and can answer 3)When assigned to a non-moisturizing group, patients who can agree not to apply moisturizing agent for a fixed period 4)Women with age from 40 to 80 who have skin dryness symptoms and a heparin analog containing preparation is indicated 5)Patients who got an explanation about the contents of this research and gained consent in writing about research participation

Exclusion criteria

Exclusion criteria: 1) Patients who are unable to cooperate with DLQI measurement 2) Patients with extensive complications or medical history of the skin, chronic skin disease 3) Patients with a history of hypersensitivity to heparin analogue-containing preparations 4) Patients scheduled to undergo chemotherapy or endocrine therapy during radiation treatment 5) Patients with collagen disease, systemic immune disease, hemorrhagic blood disease 6) Patients who are judged to be ineligible by research director, research assignee

Design outcomes

Primary

Measure	Time frame
DLQI total scores at a week after treatment completion	—

Secondary

Measure	Time frame
DLQI total score DLQI subscale NCI-CTCAE Grade (radiation dermatitis) Use of steroid cream	—

Countries

Japan

Contacts

Public ContactJiro Kawamori

St.Luke International Hospital Department of Radiation Oncology

jirokawa@luke.ac.jp03-3541-5151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026